Synergism of Rana catesbeiana ribonuclease and IFN-γ triggers distinct death machineries in different human cancer cells  by Tang, Chih-Hang Anthony et al.
FEBS 29125 FEBS Letters 579 (2005) 265–270Synergism of Rana catesbeiana ribonuclease and IFN-c triggers
distinct death machineries in diﬀerent human cancer cells
Chih-Hang Anthony Tanga,b,1, Chih-Chi Andrew Huc,1, Chyou-Wei Weia,d,1, Jaang-Jiun Wangb,e,*
a Neuromedical Scientiﬁc Center, Buddhist Tzu-Chi General Hospital, Hualien 970, Taiwan
b Institute of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan
c Department of Pharmacology, New York University School of Medicine, New York, NY 10016, USA
d Tzu-Chi College of Technology, Hualien 970, Taiwan
e The College of Medicine, Fu Jen Catholic University, 510 Chung-Cheng Rd., Hsin-Chuang, Taipei Hsien 24205, Taiwan
Received 19 September 2004; revised 22 November 2004; accepted 24 November 2004
Available online 8 December 2004
Edited by Veli-Pekka LehtoAbstract Rana catesbeiana ribonuclease (RC-RNase) pos-
sesses tumor-speciﬁc cytotoxicity, which can be synergized by
IFN-c. However, it is unclear how RC-RNase and RC-RNase/
IFN-c induce cell death. In this study, we use substrate cleavage
assays to systematically investigate RC-RNase- and RC-RNase/
IFN-c-induced caspase activation in HL-60, MCF-7, and SK-
Hep-1 cells. We ﬁnd that RC-RNase and RC-RNase/IFN-c in-
duce mitochondria-mediated caspase activation in HL-60 and
MCF-7 cells but not in SK-Hep-1 cells, although death of SK-
Hep-1 cells is closely related to mitochondrial disruptions. Our
ﬁndings provide evidence that RC-RNase and RC-RNase/IFN-
c can kill diﬀerent cancer cells by distinct mechanisms. Com-
pared with onconase, RC-RNase seems to harbor a more speciﬁc
anti-cancer activity.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Anti-tumor ribonuclease1. Introduction
Rana catesbeiana ribonuclease (RC-RNase) derived from
oocytes of R. catesbeiana and onconase from those of Rana
pipiens share 50% amino acid sequence identity and contain
an identical lectin domain that may be responsible for the
tumoricidal eﬀect of the two ribonucleases [1,2]. Cell death
machineries initiated by these frog oocyte-derived ribonucle-
ases still remain unclear.
Cellular proteases named caspases are known to mediate
apoptotic cell death and two autonomous but cross-talking
caspase activation pathways have been identiﬁed [3–5]. For
receptor-mediated apoptosis, the initiator caspase-8/execu-
tioner caspase-3 pathway is activated via binding of ligands
onto the cell surface death receptors (e.g., FasL/Fas). ForAbbreviations: XTT, sodium 3 0-[1-(phenylamino-carbonyl)-3,4-tetra-
zolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate; RC-
RNase, Rana catesbeiana ribonuclease; PARP, poly(ADP-ribose)
polymerase
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cutioner caspase-3 pathway is activated in response to homeo-
static alterations of mitochondria. As a close relative to
caspase-3, caspase-7 can also be activated by caspase-8 or cas-
pase-9 to be an executioner protease. Both caspase-3 and -7
can lead to the proteolytic cleavage of other caspases (e.g., cas-
pase-2 and -6) and numerous cellular substrates like poly
(ADP-ribose) polymerase (PARP) [3].
We have previously reported that caspase-7 is activated in
the RC-RNase-treated caspase-3-deﬁcient MCF-7 cells, while
there is no activation of its upstream caspase-9 or caspase-8;
that caspase-7 can in succession process procaspase-2, procas-
pase-6 and PARP; and that Bcl-XL, an anti-apoptotic mito-
chondrial protein, can eﬃciently rescue MCF-7 cells from
RC-RNase-induced cell death [6]. We also found that the cas-
pase-9/caspase-3 pathway is activated in RC-RNase-treated
undiﬀerentiated HL-60 cells, suggesting that RC-RNase-in-
duced caspase activation is initiated from mitochondria [7].
RC-RNase and IFN-c were found to have synergistic
tumoricidal eﬀect in three hepatoma cell lines bearing diﬀerent
diﬀerentiation stages, and such an eﬀect was shown to be espe-
cially prominent in poorly diﬀerentiated SK-Hep-1 cells [8].
Although RC-RNase/IFN-c treatment had caused a massive
death in SK-Hep-1 cells, there was neither apoptotic nor ne-
crotic feature observed in these cells [8]. Together with evi-
dence that mitochondrial disruptions were observed in HeLa
cells treated with RC-RNase (unpublished data) and in SK-
Hep-1 cells treated with RC-RNase/IFN-c [8], we suggested
that RC-RNase-induced cell death might be initiated from
mitochondrial disruptions.
In this present study, we used a more sensitive method to
systematically investigate RC-RNase- and RC-RNase/IFN-
c-induced caspase activation in HL-60, MCF-7, and SK-Hep-1
cells. We showed that RC-RNase- or RC-RNase/IFN-c-in-
duced caspase activation could vary in diﬀerent cell types, sug-
gesting that distinct death machineries were triggered. We also
showed that theRC-RNase/IFN-c regimen could bemuchmore
speciﬁc in killing tumor cells than the onconase/IFN-c regimen.2. Materials and methods
2.1. Reagents and cell culture
RC-RNase was puriﬁed using the modiﬁed methods published pre-
viously [6,9]. Caspase-3, caspase-7, PARP, and actin monoclonal anti-
bodies were purchased, respectively, from Imgenex, Oncogene,blished by Elsevier B.V. All rights reserved.
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Ac-LEHD-pNA (acetyl–Leu–Glu–His–Asp–p-nitroanilide), Ac-DE-
VD-pNA (acetyl-Asp–Glu–Val–Asp–p-nitroanilide), and Ac-IETD-
pNA (acetyl-Ile–Glu–Thr–Asp–p-nitroanilide) were purchased from
Anaspec. Sodium 3 0-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-
bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate (XTT) assay kits
were purchased from Roche. Human HL-60 promyelocytic leukemia
cells, human MCF-7 breast carcinoma cells, and human SK-Hep-1
hepatoma cells were obtained from the American Type Culture Collec-
tion and cultured in Dulbeccos modiﬁed Eagles medium (Gibco) sup-
plemented with 10% heat-inactivated fetal bovine serum (Hyclone), 2
mM L-glutamine (Gibco), 100 IU/ml penicillin G sodium (Gibco),
100 lg/ml streptomycin sulfate (Gibco), 1 mM sodium pyruvate
(Sigma), and 0.1 mM non-essential amino acids (Gibco).
2.2. Cell viability assay
Cell viability was evaluated by using XTT assays that detect activity
of mitochondrial dehydrogenases. Brieﬂy, 2 · 103 cells were grown in
each well of 96-well cell culture plates overnight. On the next day, cells
were treated with RC-RNase (20 lg/ml), onconase (20 lg/ml), IFN-c
(10 ng/ml), or the combined treatments. XTT assays were performed
every 24th hour according to the manufacturers instructions. Absor-
bance at 492 nm was determined by a multi-well ELISA reader (Molec-
ular Devices).
2.3. Caspase activity assay
Cells were resuspended in the lysis buﬀer (50 mM Tris–HCl, 120 mM
NaCl, 1 mM EDTA, and 1% NP-40, pH 7.5) supplemented with pro-
tease inhibitors. Insoluble pellets were removed by centrifugation using
15000 · g at 4 C for 20 min. The caspase activity assay was performed
in a reaction containing 40 ll cell lysates (80 lg total protein), 158 ll
reaction buﬀer (20% glycerol, 0.5 mM EDTA, 5 mM dithiothreitol,
and 100 mM HEPES, pH 7.5), and 2 ll ﬂuorogenic Ac-LEHD-pNA,
Ac-DEVD-pNA, or Ac-IETD-pNA substrates (100 lM ﬁnal concen-
tration); the reaction was incubated at 37 C for 6 h (in this condition,
all substrates were not used up and the caspase activity could be com-
pared in the linear range). The ﬂuorogenic substrate cleavage readout
was the p-nitroanilide release as detected at 405 nm in an ultra-micro-
plate reader (Bio-Tek instruments). Fold increase in caspase activity
was calculated by comparing the A405 readout from the induced sam-
ple with that from the un-induced control using the following formula:
(A405sample  A405control)/A405control.
2.4. Immunoblot analysis
Cells were harvested by cell scrapers and lysed in RIPA buﬀer (10
mM Tris–base, pH 7.4; 150 mMNaCl; 1% NP-40; 0.5% sodium deoxy-
cholate; and 0.1% SDS) containing protease inhibitors (Calbiochem).
Equal amount of the total proteins was loaded onto a SDS–PAGE
(13% acrylamide) gel, electrophoresed, and transferred to polyvinyli-
dene diﬂuoride membrane (Amersham). Membranes were blocked
with 5% skimmed milk and 1% NP-40 in TBS-T (0.8% NaCl; 0.02%
KCl; 25 mM Tris–HCl; and 0.05% Tween 20, pH 7.4) for 2 h, incu-
bated with the primary antibody (1:500 dilution in the blocking buﬀer)
at 4 C overnight, and subsequently incubated with biotinylated anti-
mouse IgG (1:2000 dilution in the blocking buﬀer) and streptavidin–
horseradish peroxidase conjugates (1:4000 dilution in TBS). The
membranes were developed using the Super Signal Chemilumines-
cent-HRP substrate system (Pierce) for protein visualization.Fig. 1. The ﬁve-day survival rates of HL-60 (A), MCF-7 (B), and SK-
Hep-1 (C) cells after RC-RNase (20 lg/ml), IFN-c (10 ng/ml), and
RC-RNase (20 lg/ml)/IFN-c (10 ng/ml) treatments. Note that RC-
RNase-induced cytotoxicity was enhanced by IFN-c inMCF-7 cells and
SK-Hep-1 cells, but not in HL-60 cells. Data were obtained from three
independent triplicate experiments and presented as means ± S.D.3. Results
3.1. IFN-c enhanced RC-RNase-induced cell death in SK-Hep-1
cells and MCF-7 cells but not in HL-60 cells
We treated HL-60, MCF-7, or SK-Hep-1 cells with RC-
RNase (20 lg/ml) and RC-RNase (20 lg/ml)/IFN-c (10 ng/
ml) for 5 days and assessed the cell viability by the XTT assay,
which measured the activity of mitochondrial dehydrogenases.
While IFN-c alone showed little adverse eﬀect on the three
cancer cell lines, RC-RNase treatments were cytotoxic to these
lines. Noticeably, RC-RNase per se could induce much moredevastating death to HL-60 cells (Fig. 1A) and MCF-7 cells
(Fig. 1B) than to SK-Hep-1 cells (Fig. 1C), suggesting that it
exerted distinct potencies to diﬀerent cancer cell lines. The
combined treatments of RC-RNase (20 lg/ml) and IFN-c
(10 ng/ml) exerted a signiﬁcant synergistic eﬀect in MCF-7
and SK-Hep-1 cells (Fig. 1B and C), but not in HL-60 cells
(Fig. 1A).
3.2. Caspase activation in HL-60, MCF-7, and SK-Hep-1 cells
after RC-RNase or RC-RNase/IFN-c treatments
We ﬁrst treated the three cell lines with RC-RNase (20 lg/
ml), IFN-c (10 ng/ml), or RC-RNase (20 lg/ml)/IFN-c (10
ng/ml) for 48 or 96 h and measured caspase activity using ﬂu-
orogenic substrate cleavage assay. We measured the caspase-9,
caspase-3-like, and caspase-8 activities by incubating cell ly-
sates, respectively, with ﬂuorogenic substrates, Ac-LEHD-
pNA, Ac-DEVD-pNA, or Ac-IETD-pNA.
In HL-60 cells, caspase-9, caspase-3-like, and caspase-8
activities were all detected after RC-RNase or RC-RNase/
IFN-c treatments (Fig. 2). Caspase-9 was fully activated in
the ﬁrst 48 h after treatments (Fig. 2A); however, caspase-3-
Fig. 3. Caspase activation in MCF-7 cells after RC-RNase (20 lg/ml),
IFN-c (10 ng/ml), or RC-RNase (20 lg/ml)/IFN-c (10 ng/ml)
treatments. Note that caspase-3-like activity signiﬁcantly increased
after treatments with RC-RNase or RC-RNase/IFN-c for 96 h, and
that IFN-c could aggravate caspase-3-like activity (B). Caspase-9 (A)
or caspase-8 (C) was not activated by any of the treatments. The data
are presented as means ± S.D. from three independent triplicate
experiments.
Fig. 2. Caspase activation in HL-60 cells after RC-RNase (20 lg/ml),
IFN-c (10 ng/ml), or RC-RNase (20 lg/ml)/IFN-c (10 ng/ml)
treatments. Note that caspase-9 (A), caspase-3-like (B), and caspase-
8 (C) activities signiﬁcantly increased after RC-RNase or RC-RNase/
IFN-c treatments; that caspase-9 was found to have been fully
activated in the ﬁrst 48 h; and that IFN-c did not aggravate caspase
activation in HL-60 cells. The data are presented as meanss ± S.D.
from three independent triplicate experiments.
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dependent fashion, in which the 96-h treatment induced a
more signiﬁcant activation of the two caspases than the 48-h
treatment (Fig. 2B and C). The earlier activation of caspase-
9 suggested that RC-RNase-induced death of HL-60
cells should be initiated from mitochondrial alterations.
Interestingly, IFN-c showed no eﬀect in enhancing the RC-
RNase-induced caspase activation in HL-60 cells.
While caspase-9 or caspase-8 activity did not increase in
MCF-7 cells after RC-RNase or RC-RNase/IFN-c treat-
ments (Fig. 3A and C), caspase-3-like activity increased sig-
niﬁcantly after both treatments for 96 h (Fig. 3B). Notably,
cells treated with RC-RNase/IFN-c had much higher cas-
pase-3-like activity than those treated with RC-RNase alone
(Fig. 3B), suggesting that IFN-c could aggravate RC-
RNase-induced death via enhancing caspase-3-like activity
in these cells. Since MCF-7 cells are caspase-3-deﬁcient, the
caspase-3-like activity detected in this cell type should repre-
sent caspase-7 activation.Previously, RC-RNase- or RC-RNase/IFN-c was shown to
induce death of SK-Hep-1 cells, which had atypical apoptotic
and necrotic features [8]. Although RC-RNase/IFN-c had
been shown to cause severe mitochondrial disruptions in SK-
Hep-1 cells [8], both RC-RNase and RC-RNase/IFN-c could
not induce changes of caspase-9 (Fig. 4A), caspase-3-like
(Fig. 4B), and caspase-8 (Fig. 4C) activities in SK-Hep-1 cells
after 48-h or 96-h treatments, indicating that such a death
mechanism has little to do with caspase activation.
3.3. A distinct executioner caspase was activated in diﬀerent cell
types after RC-RNase and RC-RNase/IFN-c treatments
In HL-60 cells that express both caspases-3 and caspase-7,
only caspase-3 was activated by RC-RNase (data not shown;
[7]) and RC-RNase/IFN-c (Fig. 5, lanes 1–3) treatments,
indicating that the increased caspase-3-like activity in RC-
RNase- and RC-RNase/IFN-c-treated HL-60 cells was
mainly due to caspase-3 activation (Fig. 2B). In the
Fig. 4. Lack of caspase activation in SK-Hep-1 cells after RC-RNase
(20 lg/ml), IFN-c (10 ng/ml), or RC-RNase (20 lg/ml)/IFN-c (10 ng/
ml) treatments. Note that none of the three treatments signiﬁcantly
altered caspase-9 (A), caspase-3-like (B), and caspase-8 (C) activities.
The data are presented as means ± S.D. from three independent
triplicate experiments.
Fig. 5. Cleavage of executioner caspases as a response to the RC-
RNase/IFN-c treatment. HL-60 cells (lanes 1–3), MCF-7 cells (lanes
4–6), and SK-Hep-1 cells (lanes 7–9) were treated with RC-RNase (20
lg/ml)/IFN-c (10 ng/ml) for 0 h (lanes 1, 4, and 7), 48 h (lanes 2, 5, and
8), and 96 h (lanes 3, 6, and 9); lysed in RIPA buﬀer; and
immunoblotted using antibodies to indicated molecules. Note that
the 32-kDa procaspase-3 but not the 35-kDa procaspase-7 was cleaved
in HL-60 cells; that the 35-kDa procaspase-7 was cleaved to generate
the 20-kDa active caspase-7 in caspase-3-deﬁcient MCF-7 cells; that
both procaspase-3 and procaspase-7 were not cleaved in SK-Hep-1
cells; and that the 116-kDa PARP was processed into an 89-kDa
fragment in HL-60 and MCF-7 cells, but not in SK-Hep-1 cells.
Detection of actin served as the protein loading control.
Fig. 6. Speciﬁc tumoricidal activity of RC-RNase. The ﬁve-day
survival rates of SK-Hep-1 cells (A) and HS-68 cells (B) were obtained
after treatments with RC-RNase (20 lg/ml), onconase (20 lg/ml),
IFN-c (10 ng/ml), or the indicated combinations. Note that RC-RNase
alone had a milder tumoricidal activity to SK-Hep-1 cells when
compared with onconase. However, the tumoricidal activity of RC-
RNase could be enhanced by IFN-c synergistically. Also note that RC-
RNase and RC-RNase/IFN-c treatments did not aﬀect the primary
HS-68 ﬁbroblasts, while onconase and onconase/IFN-c treatments did.
Data were obtained from three quadruple groups and presented as
means ± S.D.
268 C.-H.A. Tang et al. / FEBS Letters 579 (2005) 265–270caspase-3-null MCF-7 cells, caspase-7 was activated in res-
ponse to RC-RNase (data not shown; [6]) and RC-RNase/
IFN-c (Fig. 5, lanes 4–6) treatments; this suggested that
the increased caspase-3-like activity in RC-RNase- and
RC-RNase/IFN-c-treated MCF-7 cells was due to caspase-
7 activation (Fig. 3B). In SK-Hep-1 cells that express cas-
pase-3 and caspase-7, both caspases were not activated after
RC-RNase or RC-RNase/IFN-c treatments (data not shown;
Fig. 5, lanes 7–9). Such results conﬁrmed our data showing
no increased caspase-3-like activity in RC-RNase- and RC-
RNase/IFN-c-treated SK-Hep-1 cells (Fig. 4B). In addition,
while PARP could be cleaved by caspase-3 in RC-RNase-
or RC-RNase/IFN-c-treated HL-60 cells ([7]; Fig. 5, lanes
1–3) and by caspase-7 in RC-RNase- or RC-RNase/IFN-c-
treated MCF-7 cells ([6]; Fig. 5, lanes 4–6), it was not
cleaved in RC-RNase- or RC-RNase/IFN-c-treated SK-
Hep-1 cells (data not shown; Fig. 5, lanes 7–9). This again
suggested that the death mechanism activated by RC-RNase
or RC-RNase/IFN-c in SK-Hep-1 cells does not involve cas-
pase activation.3.4. Comparison between RC-RNase–induced and
onconase-induced cytotoxicity in SK-Hep-1 hepatoma
cells and primary human HS-68 foreskin ﬁbroblasts
RC-RNase has been shown to be cytotoxic to various hu-
man cancer cell lines [6–9], but not to normal or immortalized
cells, including human primary HFW ﬁbroblasts [9], human
C.-H.A. Tang et al. / FEBS Letters 579 (2005) 265–270 269primary HS-68 foreskin ﬁbroblasts (Fig. 6B), human primary
WI-38 lung ﬁbroblasts (data not shown), immortalized ham-
ster kidney BHK-21 cells [8], and immortalized murine NIH-
3T3/3 cells [9], suggesting that cytotoxicity of RC-RNase is
cancer-speciﬁc. The cytotoxicity of RC-RNase can be syner-
gized by IFN-c in three diﬀerent hepatoma cells [8] and
MCF-7 cells (Fig. 1B). Such synergistic cytotoxicity is also spe-
ciﬁc to cancer cells, since RC-RNase/IFN-c treatments do not
induce death of primary HS-68 cells (Fig. 6B) and BHK-21
cells [8]. Onconase is known to have strong tumoricidal activity
in many cancer cells [10–13], but it is shown here to be very
toxic to primary HS-68 cells (Fig. 6B). Although onconase-
induced cytotoxicity can be exacerbated by IFN-c, such exac-
erbation is minor and can aﬀect not only cancerous SK-Hep-1
cells but also primary HS-68 cells (Fig. 6A and B).4. Discussion
In RC-RNase- or RC-RNase/IFN-c-treated HL-60 cells, all
three caspases examined are activated (Fig. 2). While caspase-9
activity increases to the maximal extent in the ﬁrst 48 h and
keeps almost consistent in the total 96-h examination period
(Fig. 2A), both caspase-3 and caspase-8 activities keep increas-
ing throughout the whole period, resulting in a much more
prominent activity after 96-h treatments with RC-RNase or
RC-RNase/IFN-c (Fig. 2B and C). Together with the data
showing that caspase-3 has a more prominent eﬀect than cas-
pase-8 after 96-h treatments (Fig. 2B and C) and previous data
showing that caspase-3 is critical for caspase-8 activation in
mitochondria-mediated apoptosis [14,15], we suggest that in
RC-RNase- or RC-RNase/IFN-c-treated HL-60 cells, cas-
pase-9 is the ﬁrst to be activated and the activated caspase-9
activates caspase-3, which can in turn activate caspase-8 to am-
plify death signals and ensure the occurrence of apoptosis.
These results clearly show that RC-RNase or RC-RNase/
IFN-c induces caspase-dependent mitochondria-mediated
apoptosis in HL-60 cells.
In RC-RNase- or RC-RNase/IFN-c-treated MCF-7 cells,
caspase-7 is activated without detectable activation of the initi-
ator caspase-9 or -8 (Fig. 3) and caspase-7 is also found to pro-
cess PARP in these treated MCF-7 cells (Fig. 5). It is known
that caspase-7 can be activated not only by caspase-9 but also
by procaspase-9 because the autocatalytic intra-chain cleavage
of procaspase-9 (into capsase-9) has only mild eﬀect on its cat-
alytic activity [16,17] and the catalytic activity of procaspase-9
or caspase-9 is actually dependent on their association with the
other two members, Apaf1 and cytochrome c, in the apopto-
some [17,18]. Together with our data showing that RC-RNase
or RC-RNase/IFN-c triggers cell death by targeting mitochon-
dria [8] and that Bcl-XL can reverse RC-RNase-induced death
in MCF-7 cells [6], we suggest that RC-RNase- or RC-RNase/
IFN-c-treated MCF-7 cells may also undergo caspase-depen-
dent mitochondria-mediated apoptosis.
Although RC-RNase alone or RC-RNase/IFN-c can induce
death of SK-Hep-1 cells, there is no increased caspase-9, cas-
pase-3-like, or caspase-8 activity detected after treatments
(Fig. 4). Such results were conﬁrmed by our immunoblot data
showing lack of processing of initiator procaspase-9 or -8 (data
not shown), executioner procaspase-3 or -7 (Fig. 5), and PARP
(Fig. 5) in RC-RNase/IFN-c-treated SK-Hep-1 cells. Together
with our previous electron microscopy data showing majormitochondrial disruptions in RC-RNase/IFN-c-treated SK-
Hep-1 cells [8], we suggest that RC-RNase and RC-RNase/
IFN-c may induce death in SK-Hep-1 cells by activating a
novel caspase-independent death pathway, which is closely
related to homeostatic alterations of mitochondria.
Iordanov et al. [19] showed that the caspase-9/caspase-3 cas-
cade was activated in onconase-treated HeLa tk cells
although activation of this caspase cascade could only be ob-
served when onconase was delivered using a lipofectin-facili-
tated method. Together with the data showing release of
procaspase-9 from mitochondria upon onconase treatment,
they suggested that onconase induced apoptosis via mitochon-
dria-mediated caspase activation [19]. By using a pan-caspase
inhibitor, Grabarek et al. [20] later showed that caspases were
indeed activated in HL-60 cells undergoing onconase-induced
apoptosis; however, the activated caspases were not further
characterized. In this present study, we systematically investi-
gated caspase activation in three diﬀerent cell lines treated with
RC-RNase, which like onconase is also a cytotoxic ribonucle-
ase derived from frog oocytes. We found that RC-RNase
could induce not only caspase-dependent mitochondria-medi-
ated apoptosis (e.g., in HL-60 and MCF-7 cells) but also cas-
pase-independent mitochondria-mediated apoptosis (e.g., in
SK-Hep-1 cells). Since RC-RNase and onconase are closely re-
lated, it is very likely that both can induce death in diﬀerent
cancer cells using distinct mechanisms.
RC-RNase induces distinct degree of cytotoxicity in HL-60,
MCF-7, and SK-Hep-1 cells, possibly because these cell lines
have diﬀerent diﬀerentiation stages. We have previously
studied three diﬀerent hepatoma cell lines bearing distinct dif-
ferentiation stages and reported that RC-RNase-induced
cytotoxicity is diﬀerentiation-dependent but not prolifera-
tion-dependent [8]. Our recent study also showed that induc-
tion of diﬀerentiation can rescue HL-60 cells from
RC-RNase-induced cytotoxicity [7]. We therefore suggest that
the diﬀerent degree of RC-RNase-induced cytotoxicity in HL-
60, MCF-7, and SK-Hep-1 cells might also depend on the
intrinsic diﬀerentiation status of these three cell lines. If we
can further show that RC-RNase-induced cytotoxicity is also
diﬀerentiation-dependent in many other cell types, we think
RC-RNase might be able to serve as a useful tool in deﬁning
the intrinsic diﬀerentiation status of cell lines derived from dif-
ferent tissues.
IFN-c has been shown to synergize the RC-RNase-induced
cytotoxicity; however, this synergistic cytotoxicity is not seen
in the HL-60 cells (Fig. 1A). Since RC-RNase-induced cell
death is diﬀerentiation-dependent [7,8] and IFN-c is known
to induce diﬀerentiation of HL-60 cells [21–23], we suggest
the reason why there is no synergistic cytotoxicity of RC-
RNase and IFN-c in this cell type might be because the diﬀer-
entiation status of HL-60 cells has been altered by IFN-c and
such a change in the diﬀerentiation status protects these cells
from the synergistic cytotoxicity.
RC-RNase and RC-RNase/IFN-c have been shown to be
non-toxic to a panel of normal or immortalized cells. Com-
pared with onconase in this study, RC-RNase and RC-
RNase/IFN-c treatments clearly have more tumor-speciﬁc
cytotoxicity (Fig. 6). While onconase has reached Phase III
clinical trials in the US as an anti-cancer drug [24,25], we be-
lieve that RC-RNase can also be a promising drug for cancer
therapy. Since diﬀerent cytotoxicity and caspase activation
have been observed in HL-60, MCF-7, and SK-Hep-1 cells
270 C.-H.A. Tang et al. / FEBS Letters 579 (2005) 265–270after RC-RNase and RC-RNase/IFN-c treatments, the tumor-
icidal mechanisms of RC-RNase and RC-RNase/IFN-c re-
quire deliberate investigation before we pursue their clinical
applications.
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